Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data Medicenna Therapeutics Corp. files with the SEC in its annual reports.
In CAD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
Research and development
5.87
10.9
14.7
9.3
Pre-tax income
-8.28
-17.3
-22.6
-10
Income tax
0
0
0
0
Net income
-8.28
-17.3
-22.6
-10
EPS, basic
-0.26
-0.35
-0.42
-0.16
EPS, diluted
-0.26
-0.35
-0.42
-0.16
Balance sheet
FY2021
FY2021
FY2022
FY2023
Cash and equivalents
22.7
30.4
20.5
33.6
Total current assets
37.9
42.1
23.4
36.4
Lease right-of-use assets
0.07
0.03
0
Intangible assets
0.08
0.07
0.07
0.06
Total assets
38
42.3
23.5
36.4
Accounts payable
1.78
4.07
2.62
3.8
Total current liabilities
1.82
4.11
2.62
3.8
Lease liabilities
0.03
0.03
0
Total liabilities
1.85
4.11
2.62
6.96
Paid-in capital
10.4
6.68
7.93
9.49
Retained earnings
-31.1
-48.4
-70.9
-81
Total equity
36.1
38.1
20.8
29.5
Total liabilities and equity
38
42.3
23.5
36.4
Cash flow statement
FY2021
FY2021
FY2022
FY2023
Net income
-8.28
-17.3
-22.6
-10
Cash from operations
-5.42
-15.3
-23.6
Cash from investing
-15
5.01
10.1
Stock issued
38.4
11.4
3.51
Cash from financing
40.7
18.3
3.88
Exchange rate effect
-0
-0.28
-0.18
Net change in cash
20.3
7.68
-9.84
Key metrics
Worked out from the statements above. Latest values use fiscal 2023. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-33.5%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
55.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-1.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
9.58x
Current assets / current liabilities.
Quick ratio
8.84x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
8.84x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
19.1%
Total liabilities / total assets.
Working capital
CA$32.6M
Current assets - current liabilities.
Goodwill and intangibles / assets
0.2%
(Goodwill + intangible assets) / total assets.
Per share
Metric
Value
How it is calculated
EPS, diluted
-CA$0.16
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-CA$0.16
Net income per basic share, as reported (split-adjusted).
Was Medicenna Therapeutics Corp. profitable in fiscal 2023?
No. It reported a net loss of CA$10.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.